PUBLISHER: Fortune Business Insights Pvt. Ltd. | PRODUCT CODE: 1930128
PUBLISHER: Fortune Business Insights Pvt. Ltd. | PRODUCT CODE: 1930128
The global urinary incontinence devices market is poised for steady growth in the coming decade, driven by rising awareness, technological innovations, and increasing prevalence of chronic conditions. According to Fortune Business Insights, the market was valued at USD 4.53 billion in 2025 and is projected to grow to USD 4.7 billion in 2026, eventually reaching USD 7.48 billion by 2034, representing a CAGR of 6.0% during the forecast period. In 2025, North America dominated the market with a 42.5% share, reflecting the region's advanced healthcare infrastructure, favorable reimbursement policies, and strong technological adoption.
Urinary incontinence devices help prevent urine leakage, improve comfort, and enhance mobility and independence, particularly among the aging population. The rising prevalence of conditions such as diabetes, obesity, urinary tract infections, and neurological disorders is increasing the demand for these devices globally. For example, as per 2025 data published by ScienceDirect, approximately 40% of the population in Europe suffers from urinary incontinence. Key players including Coloplast A/S, Convatec Inc., and Essity Aktiebolag are actively focusing on R&D initiatives to develop innovative and technologically advanced products to enhance patient care.
Market Dynamics
Drivers
The growing incidence of acute and chronic diseases, coupled with an aging population, is a major driver of market growth. According to the NCBI (2025), the global prevalence of urinary incontinence was around 32.4%, highlighting the widespread need for effective solutions. Rising awareness, reduced stigma, and better reimbursement policies further encourage adoption. By 2030, one in six people globally is expected to be aged 60 or above, supporting the long-term demand for these devices.
Restraints
Market growth is constrained by limited diagnosis and reimbursement policies in developing nations, particularly in Brazil, China, and India. Delayed referrals and a lack of clinical expertise in chronic conditions result in postponed diagnosis and treatment. For instance, the Brazilian Public Health System does not cover pharmacotherapy for urge urinary incontinence, limiting access to advanced devices in the region.
Opportunities
Technological innovations in absorbent and non-absorbent products, including smart sensors, mobile apps, and non-invasive neuromodulation devices, are reshaping the market. For example, in February 2025, UroMems announced that female patients treated with UroActive Smart Implants successfully reached six-month primary endpoints, demonstrating clinical effectiveness. These advancements provide opportunities for key players to expand their portfolios and address unmet patient needs.
Challenges
High device costs hinder adoption, especially in emerging economies. Urinary incontinence slings range from USD 10 to over USD 10,000, limiting patient access. Additional challenges include surgical risks, device failures, regulatory hurdles, and competition from alternative treatments like behavioral therapy or pharmacological options.
Market Trends
A notable trend is the shift toward minimally invasive surgeries, driven by faster recovery, reduced pain, and shorter hospital stays. Technologies such as mid-urethral slings and robotic-assisted platforms are gaining traction. According to a 2024 study by the International Continence Society, mid-urethral sling insertions showed reoperation rates of only 0.8% at one year and 2.7% at five years, highlighting improved outcomes and patient satisfaction.
By Product Type
The market is segmented into absorbents and non-absorbents, with absorbents-including underwear, briefs, pads, and bed protectors-dominating 67.02% of the market in 2026. Non-absorbent products include slings, catheters, urethral inserts, stimulation devices, and drainage bags.
By Gender
The female segment dominated in 2026 with a 64.89% share, due to higher prevalence rates among women. According to 2025 Phoenix Physical Therapy data, one in four women over 18 in the U.S. experiences some form of urinary incontinence. The male segment is projected to grow at a CAGR of 4.9% during the forecast period.
By Usage
The disposable segment led in 2026 with 58.3% share, driven by convenience and hygiene benefits. Reusable products are expected to grow at a CAGR of 5.4%.
By End User
Homecare settings dominated in 2025, with an anticipated 44.47% market share in 2026, due to patient preference for at-home treatment and adequate reimbursement policies. Hospitals and ASCs are projected to grow at a CAGR of 5.7%.
Competitive Landscape
The market is highly competitive, led by Essity Aktiebolag, Medtronic, Coloplast A/S, BD, Teleflex, and Johnson & Johnson, who focus on product innovation, regulatory approvals, and geographic expansion. Notable developments include:
Conclusion
The global urinary incontinence devices market is projected to grow from USD 4.53 billion in 2025 to USD 7.48 billion by 2034, driven by rising prevalence of chronic conditions, technological advancements, and homecare adoption. While challenges such as high device costs and limited reimbursement in emerging markets persist, innovations in minimally invasive devices, smart sensors, and patient-centric solutions are expected to significantly expand market penetration and improve patient outcomes worldwide.
Segmentation By Product Type, Gender, Usage, End User, and Region
By Product Type * Absorbents
By Gender * Male
By Usage * Reusable
By End User * Hospitals & ASCs
By Region * North America (By Product Type, Gender, Usage, End User, and Country)